ImmunoLogic Inc.

Creating therapies for inflammatory diseases including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS

The University of Colorado Connection

ImmunoLogic is creating therapies for inflammatory diseases, including Rheumatoid Arthritis, Multiple Sclerosis (MS) and ALS. The company is developing a novel oral prodrug targeted to inflammation and oxidative stress sites. ImmunoLogic was co-founded by Linda Watkins (CU ÌÇÐÄVlogÆƽâ°æ Psychology and Neuroscience) and has jointly developed intellectual property related to therapies for ALS and MS with CU ÌÇÐÄVlogÆƽâ°æ and MD Anderson Cancer Center.

Funding Status and Investment Opportunities

  • Industry: Biotech​, Therapeutics
  • Funding Stage: Pre-Seed
  • Contact for Investment Inquiries:ÌýJohn Forsayeth

In the News

More Startups News

Venture Partners Programs​

Path to CommercializationÌý

ÌýÌý ÌýThis page was last updated on Oct. 18, 2024. Please contact us for corrections or updates

The Insider Investor E-Newsletter

The InsiderÌýisÌýVenture Partners at CU ÌÇÐÄVlogÆƽâ°æ's monthly newsletter featuring theÌýlatest headlines, news, events, opportunities and emerging innovations from the university. We have several editions for our audiences.

Subscribe to The InsiderÌýÌý

Questions about investment opportunities?

Amy Dodenhoff

Amy Dodenhoff · Director of Venture Development

Contact AmyÌý

Media Inquiries

For marketing and communication inquiries, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at CU ÌÇÐÄVlogÆƽâ°æ.

For media inquiries, please visit .